Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients.
Conclusion: We conclude that high LEF1 expression was a favorable prognostic marker which can define AML patient risk and outcome independent from assessing the serum galectin.3 level.
PMID: 31929803 [PubMed]
Source: Advances in Hematology - Category: Hematology Tags: Adv Hematol Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Egypt Health | Hematology | Leukemia | Study